Close Menu

NEW YORK – Invitae reported after the close of the market Wednesday that its fourth quarter 2019 revenues increased 47 percent from the prior year.

For the three months ended Dec. 31, 2019, Invitae reported $66.3 million in revenues compared to $45.4 million in Q4 2018, falling short of the consensus Wall Street estimate of $68.1 million. Invitae reported testing revenue of $65.1 million for the quarter, as well as $1.2 million in other revenue.

Invitae accessioned around 148,000 samples in Q4 2019 compared to more than 87,000 samples in Q4 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.